EF Hutton Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Enlivex Therapeutics (NASDAQ:ENLV) and maintained a price target of $13.
September 24, 2024 | 2:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Enlivex Therapeutics and maintained a price target of $13, indicating confidence in the company's potential for growth.
The reaffirmation of a Buy rating and a $13 price target by EF Hutton suggests a positive outlook for Enlivex Therapeutics. This can boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100